Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism

NDT Plus

Volumn 1, Issue SUPPL.3, 2008, Pages

  Tanaka, Motoko ^a   Nakanishi, Shohei ^b   Komaba, Hirotaka ^c   Itoh, Kazuko ^a   Matsushita, Kazutaka ^a   Fukagawa, Masafumi ^c  

^a Akebono Clinic   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cinacalcet; Haemodialysis; Nodular hyperplasia; Secondary hyperparathyroidism; Ultrasonography

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D DERIVATIVE;

ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FOLLOW UP; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; NODULAR HYPERPLASIA; ORGAN SIZE; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

EID: 48749132022     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn087     Document Type: Article

References (23)

1. Tominaga Y, Tanaka Y, Sato K et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13: 78-86
2. Arnold A, Brown MF, Urena P et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95: 2047-2053
3. Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25-dihydroxyvitamin D3 receptor density associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443
4. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51: 328-336
5. Fukagawa M, Kitaoka M, Inazawa T et al. Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects. Curr Opin Nephrol Hypertens 1997; 6: 349-355
6. Tominaga Y, Inaguma D, Matsuoka S et al. PTG Study Group: Is the volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 2006; 10: 198-204
7. Fukagawa M, Kitaoka M, Kurokawa K. Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: a theoretical approach. Nephrol Dial Transplant 1996; 11(Suppl 3): 125-129
8. Tanaka M, Itoh K, Matsushita K et al. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism. Nephron Clin Pract 2006; 102: c1-c7
9. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
10. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807
11. Fukagawa M, Yumita S, Akizawa T et al. KRN1493 Study Group: cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008; 23: 328-335
12. Colloton M. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467-476
13. Lomonte C, Vernaglione L, Chimienti D et al. Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism? Clin J Am Soc Nephrol 2008; 3: 794-799
14. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
15. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int 2005; 67: 1179-1187
16. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771
17. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800
18. Fukagawa M, Taniguchi M. Can calcimimetics inhibit nodular hyperplasia of parathyroid glands? Nephrol Dial Transplant 2008; 23: 407-408
19. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007; 22: 577-583
20. Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 323-326
21. Kruse AE, Eisenberger U, Frey FJ et al. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007; 22: 2362-2365
22. Narayan R, Perkins RM, Berbano EP et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007; 49: 801-813
23. Garside R, Pitt M, Anderson R et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007; 22: 1428-1436